Ann: UK Distribution Agreement with Grow Biotech and IPS, page-9

This was not MXC's fault for the delays, this was because of the government restricting the international trade of cannabis. Cannabis has been at a very high demand for consumers who are sick and wanted treatment. The legal system is very complex to beat and MXC has smashed through that hurdle. Nowadays, countries, even where MXC is importing and exporting cannabis or any associated products is becoming less restricted. Legalisation and decriminalisation of cannabis is an effective way to eliminate organized crime which put mobsters out of business. MGC Pharmaceuticals are ahead of competitors as peers would have to step in through approvals and all the miserable paperwork to go through. This boosts company profit and reduces overhead costs. In addition, the Korean deal that was disorganised is a smaller problem even if many shareholders complained. I forgive MXC as the past is the past. Patience pays off what you want plus interest.